Use of Reticulocyte Hemoglobin in Anemia Assessment

3/11/2015
12:00 PM to 1:00PM (Americas) Central Time (US & Canada)

Denise Uettwiller-Geiger, Ph.D, DLM (ASCP) Director of Clinical Trials, John T. Mather Memorial Hospital, Port Jefferson, NY

Iron deficiency is the leading cause of anemia worldwide. Reticulocyte hemoglobin content (RET-He) is a direct assessment of the incorporation of iron into erythrocyte hemoglobin that provides useful information to clinicians for the diagnosis and treatment of iron-deficient states. This session will describe how reticulocyte hemoglobin (RET-He/CHr) has been shown to be more sensitive and predictive than the traditional anemia-defining guidelines in screening for iron deficiency and monitoring response to therapy.

Objectives:

  • Identify strategies to help clinicians better understand wellness, prevention, and chronic disease management of anemia using RET-He
  • Discuss the RET-He threshold for defining iron insufficiency
  • Recognize the value of RET-He for clinicians in monitoring iron deficiency, iron deficiency anemia, and Erythropoietin Stimulating Agents (ESA) therapy
  • Understand the impact of successful laboratory utilization control on financial performance
We regret the CEU credits for this webinar are no longer available.The American Society for Clinical Laboratory science(ASCLS) does not accept credits under the PACE program beyond 3 years. If you need additional assistance, please contact us at communications@sysmex.com
© Copyright Sysmex